The DOI matches its Crossref record; 27 of the 28 references it cites were found in a registry or an index.
High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among U.S. Veterans
Open accessAbstract
Background and objectives: The relationship between HDL cholesterol and all-cause mortality in patients with kidney disease is not clear. We sought to characterize the relationship of HDL cholesterol and risk of death and examine the association by eGFR levels. Design, setting, participants, & measurements: We built a cohort of 1,764,986 men who were United States veterans with at least one eGFR between October of 2003 and September of 2004 and followed them until September of 2013 or death. Results: Patients with low HDL cholesterol and low eGFR had a higher burden of comorbid illnesses. Over a median of 9.1 years (interquartile range, 7.7–9.4 years), 26,247 (40.1%), 109,222 (32.3%), 152,625 (29.2%), 113,785 (28.5%), and 139,803 (31.8%) participants with HDL cholesterol ≤25, >25 to <34, ≥34 to ≤42, >42 to <50, and ≥50 mg/dl died. In adjusted survival models, compared with the referent group of patients with low HDL cholesterol (≤25 mg/dl), intermediate HDL cholesterol levels (>25 to <34, ≥34 to ≤42, and >42 to <50 mg/dl) were associated with lower risk of death across all levels of eGFR. The lower risk was partially abrogated in those with high HDL cholesterol (≥50 mg/dl), and the risk of death was similar to the referent category among those with eGFR<30 or ≥90 ml/min per 1.73 m 2 . Analysis by HDL cholesterol deciles and spline analyses suggest that the relationship between HDL cholesterol and death follows a U-shaped curve. There was a significant interaction between eGFR and HDL cholesterol in that lower eGFR attenuated the salutary association of HDL cholesterol and risk of death ( P for interaction <0.01). Presence of coronary artery disease attenuated the lower risk of high HDL cholesterol and all-cause mortality in those with eGFR≥60 ml/min per 1.73 m 2 ( P for interaction <0.05). Conclusions: Our results show a U-shaped relationship between HDL cholesterol and risk of all-cause mortality across all eGFR categories. The risk is modified by eGFR and cardiovascular disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A recent register study of more than 1 million US veterans found a U-shaped relationship between HDL-C and total mortality with 50 mg/dL (1.25 mmol/L) as the nadir associated with the lowest mortality [76].”
From Comparisons of the effects of different flaxseed products consumption on lipid profiles, inflammatory cytokines and anthropometric indices in patients with dyslipidemia related diseases: systematic review and a dose-response meta-analysis of randomized controlled trials (2021) · cites this paper as [76]
Experimental — accuracy not yet measuredIn the citing paper
“A recent register study of more than 1 million US veterans found a U-shaped relationship between HDL-C and total mortality with 50 mg/dL (1.25 mmol/L) as the nadir associated with the lowest mortality [5].”
From HDL cholesterol: reappraisal of its clinical relevance (2017) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data
Quan, H., Sundararajan, V., Halfon, P., Fong, A., Burnand, B., Luthi, J.-C., Saunders, L. D., Beck, C. A., Feasby, T. E., & Ghali, W. A. (2005) · Medical Care · doi:10.1097/01.mlr.0000182534.19832.83 · Cited by 10,669
A formula to estimate the approximate surface area if height and weight be known. 1916.
Bois, D. D., & Bois, E. F. D. (1989) · PubMed · Cited by 5,303
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Muntner, P., Coresh, J., Smith, J. C., Eckfeldt, J., & Klag, M. J. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00165.x · Cited by 667
Proton Pump Inhibitors and Risk of Incident CKD and Progression to ESRD
Xie, Y., Bowe, B. C., Li, T., Xian, H., Balasubramanian, S., & Al‐Aly, Z. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015121377 · Cited by 334
Self-citationSpeer, T., Rohrer, L., Blyszczuk, P., Shroff, R., Kuschnerus, K., Kränkel, N., Kania, G., Zewinger, S., Akhmedov, A., Shi, Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.02.009 · Cited by 310
Trevisan, R., Dodesini, A. R., & Lepore, G. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005121320 · Cited by 246
Dysfunctional High-Density Lipoprotein in Patients on Chronic Hemodialysis
Yamamoto, S., Yancey, P. G., Ikizler, T. A., Jerome, W. G., Kaseda, R., Cox, B. E., Bian, A., Shintani, A., Fogo, A. B., Linton, M. F., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.09.013 · Cited by 197
Flagged first, then by citations
1 of the 28 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: A Mendelian randomisation study., Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 213
Chang, T. I., Streja, E., Soohoo, M., Ko, G. J., Rhee, C. M., Kovesdy, C. P., Kashyap, M. L., Vaziri, N. D., Kalantar‐Zadeh, K., & Moradi, H. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.01.010 · Cited by 17
Ding, M., Wennberg, A. M. V., Ek, S., Santoni, G., Gigante, B., Walldius, G., Hammar, N., & Modig, K. (2021) · Scientific Reports · doi:10.1038/s41598-021-03959-5 · Cited by 16
Zhang, Q., Ke, Y., & Hong, H. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-1592-5_4 · Cited by 17
Suematsu, Y., Goto, M., Park, C., Nunes, A. C. F., Jing, W., Streja, E., Rhee, C. M., Cruz, S., Kashyap, M. L., Vaziri, N. D., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00334 · Cited by 16
Chen, C., Liu, X., Liu, L., Lo, K. K.-H., Yu, Y., Huang, J., Huang, Y., & Chen, J. (2020) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s272624 · Cited by 15
High Free Cholesterol Bioavailability Drives the Tissue Pathologies in Scarb1 −/− Mice
Liu, J., Gillard, B. K., Yelamanchili, D., Gotto, A. M., Rosales, C., & Pownall, H. J. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.316535 · Cited by 16
Zhang, G., Guo, J., Jin, H., Wei, X., Zhu, X., Jia, W., & Huang, Y. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1201107 · Cited by 15
Wang, Y., Li, W., Zhao, Z., Yin, S., Tang, X., & Zhang, K. (2024) · BMC Cardiovascular Disorders · doi:10.1186/s12872-024-04446-1 · Cited by 15
Heine, G. H., Rogacev, K. S., Weingärtner, O., & Marsche, G. (2017) · Seminars in Dialysis · doi:10.1111/sdi.12621 · Cited by 13
The Effects of Exercise on Lipid Biomarkers
Mendoza, M. F., Kachur, S. M., & Lavie, C. J. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1558-4_6 · Cited by 12
Impact of Lipoproteins on Atherobiology
Ma, F., Rached, F. H., Kontush, A., & Chapman, M. J. (2018) · Cardiology Clinics · doi:10.1016/j.ccl.2017.10.001 · Cited by 12
Lamprea-Montealegre, J. A., McClelland, R. L., Otvos, J. D., Mora, S., Koch, M., Jensen, M. K., & de Boer, I. H. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.013713 · Cited by 12
Kaur, M., Ahuja, K. R., Khubber, S., Zhou, L., Verma, B. R., Meenakshisundaram, C., Gad, M. M., Saad, A. M., Dhaliwal, K., Isogai, T., et al. (2021) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2021.01.014 · Cited by 12
Cholesterol: Can’t Live With It, Can’t Live Without It
Pownall, H. J., & Gotto, A. M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-9 · Cited by 11
Serum high density lipoprotein cholesterol level and risk of death: let’s avoid the extremes
Moradi, H., Streja, E., & Kalantar‐Zadeh, K. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.155 · Cited by 11
High-density lipoprotein: our elusive friend
Asztalos, B. F., Niisuke, K., & Horvath, K. V. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000612 · Cited by 11
Dyslipidemia in Chronic Kidney Disease
Streja, E., & Streja, D. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch34 · Cited by 11
Kalwick, M., & Roth, M. M. (2025) · Nutrients · doi:10.3390/nu17040659 · Cited by 13
HDL-C, longitudinal change and risk of mortality in a Chinese cohort study
Yang, Z., Wu, M., Lu, J., Zhu, Y., Li, D., Yu, Z., Shen, P., Tang, M., Jin, M., Lin, H., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.06.004 · Cited by 10
Yang, H. S., Jeong, H. J., Kim, H., Hwang, H. K., Hur, M., & Lee, S. (2022) · Annals of Laboratory Medicine · doi:10.3343/alm.2022.42.4.415 · Cited by 10
Yan, Y.-Q., Chen, J., & Huang, Y. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s313006 · Cited by 10
Suh, S.-H.-O., Oh, T. R., Choi, H.-S., Kim, C., Bae, E., Ma, S., Oh, K., Han, S., & Kim, S. (2022) · Nutrients · doi:10.3390/nu14183792 · Cited by 11
Kunutsor, S. K., & Laukkanen, J. A. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac272 · Cited by 10
High-density lipoprotein in cardiovascular diseases: From high quantity to high quality
Zhang, Y., Yu, M., Chen, Y., & Huang, J. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120574 · Cited by 10
High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?
von Eckardstein, A. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_536 · Cited by 9
Clinical associations between exercise and lipoproteins
Mendoza, M. F., & Lavie, C. J. (2022) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000848 · Cited by 9
Ou, J., Li, H.-M., Shi, M., & Ou, Z. (2020) · Springer eBooks · doi:10.1007/978-3-319-69892-2_1054-1 · Cited by 9
Franczyk, B., Młynarska, E., Rysz-Górzyńska, M., Gluba-Brzózka, A., Rysz, J., Sheth, S., Surma, S., Banach, M., & Toth, P. P. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101068 · Cited by 10
Yelamanchili, D., Gillard, B. K., Gotto, A. M., Cainzos‐Achirica, M., Nasir, K., Remaley, A. T., Rosales, C., & Pownall, H. J. (2024) · Journal of Lipid Research · doi:10.1016/j.jlr.2024.100707 · Cited by 8
Lipid Metabolism in Dyslipidemia and Familial Hypercholesterolemia
Badimón, L., & Chiva‐Blanch, G. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811297-7.00024-x · Cited by 8
Huang, K., Wen, X.-Q., Ren, N., Yang, L., & Gao, B. (2021) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2202052 · Cited by 8
Liu, L., Han, M., Qie, R., Li, Q., Zhang, X., Zhang, J., Zhan, S., Zhang, L., Xu, Z., Zhang, C., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-021-01690-6 · Cited by 9
Wei, L., Sun, J., Xie, H., Zhuang, Q., Wei, P., Zhao, X., Chen, Y., Dong, J.-Y., Li, M., Chen, C., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.819274 · Cited by 8
Kobayashi, G., Okada, H., Hamaguchi, M., Kurogi, K., Murata, H., Ito, M., & Fukui, M. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.957728 · Cited by 8
Kunutsor, S., Bhattacharjee, A., Connelly, M., Bakker, S. J., & Dullaart, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042290 · Cited by 8
High-density lipoprotein: quantity or quality?
Τζιόμαλος, Κ. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.11.67 · Cited by 7
The pathophysiology of excess plasma-free cholesterol
Gillard, B. K., Rosales, C., Gotto, A. M., & Pownall, H. J. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000899 · Cited by 7
Mendoza, M. F., Suan, N. M., & Lavie, C. J. (2024) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk9030131 · Cited by 11
Niisuke, K., Horvath, K. V., & Asztalos, B. F. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000529 · Cited by 7
Angeborene Störungen des High-density-Lipoprotein-Stoffwechsels
von Eckardstein, A. (2019) · Der Internist · doi:10.1007/s00108-019-00700-3 · Cited by 7
Ganjali, S., Mahdipour, E., Aghaee‐Bakhtiari, S. H., Ghayour‐Mobarhan, M., Soflaei, S. S., Banach, M., Kontush, A., & Sahebkar, A. (2021) · Archives of Medical Science · doi:10.5114/aoms/140728 · Cited by 7
Badimón, L., Padró, T., & Cubedo, J. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000441 · Cited by 7
Lipid cutoffs for increased cardiovascular disease risk in non-diabetic young people
Kim, M. K., Han, K., Kim, H., Yoon, K., & Lee, S. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac139 · Cited by 7
Li, S., Fu, Z., & Zhang, W. (2025) · BMC Public Health · doi:10.1186/s12889-025-22251-z · Cited by 6
Zeng, C., Yan, C., Guo, S., Zhu, H., Chen, Y., & Zhan, X. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.09.008 · Cited by 6
Davis, T. M. E., Chubb, S. A. P., & Davis, W. A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02447-0 · Cited by 5
Ewere, E. G., Okolie, N. P., Avan, E. D., & Umoh, P. E. (2021) · Clinical Phytoscience · doi:10.1186/s40816-020-00241-5 · Cited by 5
Perakakis, N., Funk, A. M., Kolb, T., Jonas, S., Hellerhoff, I., Tam, F. I., Bornstein, S. R., Chavakis, T., Mirtschink, P., & Ehrlich, S. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.01.014 · Cited by 5
Pryor, J. B., Weber, B. R., Weber, J. V., Lockridge, J. B., & Olyaei, A. J. (2019) · Drugs & Therapy Perspectives · doi:10.1007/s40267-019-00646-4 · Cited by 5
Huang, Y., Li, Y., Wu, Z., Liang, Y., & He, J. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02346-z · Cited by 4
Quality over Quantity: A Case Based Review of HDL Function and Dysfunction
Suleiman, S., Coughlan, J. J., & Vincent, M.-H. (2020) · International Journal of Clinical Cardiology · doi:10.23937/2378-2951/1410176 · Cited by 3
Functional diversity of high-density lipoproteins: finding the golden mean
Metelskaya, V. A. (2021) · Ateroscleroz · doi:10.52727/2078-256x-2021-17-2-61-71 · Cited by 4
Zheng, Y., Wu, T., Hou, X., Yang, Y., Yang, H.-T., Pan, Y., Xiu, W., Ma, X., Ma, Y., Yang, X.-L., et al. (2023) · Thrombosis and Haemostasis · doi:10.1055/a-2104-1693 · Cited by 3
Honda, Y., Maruyama, Y., Nakamura, M., Nakao, M., Matsuo, N., Tanno, Y., Ohkido, I., Ikeda, M., & Yokoo, T. (2022) · Therapeutic apheresis and dialysis · doi:10.1111/1744-9987.13821 · Cited by 3
CSL112 and HDL function hypothesis – a never-ending wait
Zaman, M. A., Kalsoom, S., & Koran, W. (2024) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2024.2378763 · Cited by 3
Darabi, M., Zakiev, E., & Kontush, A. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_18 · Cited by 3
Commentary: Big data bring big controversies: HDL cholesterol and mortality
Ala‐Korpela, M., Kuusisto, S. M., & Holmes, M. V. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab016 · Cited by 3
Current Perspectives of Diabetic Dyslipidemia and Treatment Modalities
Akkuş, G. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673336501241001093417 · Cited by 2
Call for a consensual definition of dyslipidemia in coronary angiography trials
Clerc, A., Togni, M., & Cook, S. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1506149 · Cited by 2
Kunutsor, S. K., Connelly, M. A., Shah, A. H., Bakker, S. J. L., & Dullaart, R. P. F. (2025) · Journal of Hypertension · doi:10.1097/hjh.0000000000004014 · Cited by 2
Zhang, Y., Liang, J., Li, S. X., Ma, K., Zhang, D., Chen, W. X., Liu, Q. Y., & Yu, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1827345 · Cited by 2
High density lipoproteins and kidney function: the friend turned foe?
Badimón, L., Vilahur, G., & Cubedo, J. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.11.66 · Cited by 2
Bao, F., Yang, C., & Zhou, G. (2021) · PubMed Central · doi:10.13201/j.issn.2096-7993.2021.12.005 · Cited by 2
Effect of Hormone Therapy on Lipoprotein Subfractions in Early and Late Postmenopausal Women
Sriprasert, I., Kim, S. S., Mohammed, I. E., Kono, N., Karim, R., Allayee, H., Hodis, H. N., Mack, W. J., & Krauss, R. M. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae171 · Cited by 2
High density lipoprotein cholesterol and risk of death
Al‐Aly, Z. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.12.65 · Cited by 2
Self-citationA Novel Biomarker Approach to Exploit HDL for Risk Assessment
von Eckardstein, A. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.02.040 · Cited by 2
Richardson, K. A., Richardson, L. T., & Bowden, R. G. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2030037 · Cited by 2
Shimasaki, Y., & Nojima, M. (2025) · AJPM Focus · doi:10.1016/j.focus.2025.100380 · Cited by 1
Qiu, S., Zhu, J., Yuan, M., & Guo, Z. (2025) · Population Health Metrics · doi:10.1186/s12963-025-00396-8 · Cited by 1
Kunutsor, S. K., Connelly, M. A., Bakker, S. J. L., & Dullaart, R. P. F. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02668-6 · Cited by 1
Fierfas, F., Bahls, M., Henning, A., Petersmann, A., Budde, K., Dörr, M., Völzke, H., Nauck, M., Hannemann, A., & Friedrich, N. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02779-0 · Cited by 1
Lou, X., Guo, R., Cao, Y., & Zhao, W. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05254-x · Cited by 1
Laukkanen, J. A., Kurl, S., Ravandi, A., Kauhanen, J., & Kunutsor, S. K. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104706 · Cited by 1
Unmet Cardiovascular Risk Beyond LDL-C: A Perspective on Managing Residual Cardiovascular Risk
Kypreos, K. E., Gafencu, A. V., Andreopoulou, O., Zvintzou, E., Marinos, K., Mparnia, V., Alemi, M., Daraban, B. S., Multescu, M. G., Ghinea, M., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19071071 · Cited by 2
Hypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · Praxis · doi:10.1024/1661-8157/a002760 · Cited by 1
Taravatmanesh, S., Parsa, N., Trevisan, M., & Zaheri, P. M. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.5.1361 · Cited by 1
Updated Clinical Guide to Exercise and Lipids
Mendoza, M. F., Kachur, S. M., & Lavie, C. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00015-7 · Cited by 1
Qi, L., Zhang, A., Zhang, Y., Ren, Z., Chen, Z., Wang, Q., Ren, K., Bai, J., & Cao, N. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-078981 · Cited by 1
Li, Y., Ge, J., Geng, S., Li, Q., Chen, X., Zhu, Y., Guo, X., Gu, H., & Liu, Y. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-025-02545-2 · Cited by 1
Ribas-Seguí, D., Forcadell-Peris, M. J., Vila-Córcoles, Á., de Diego‐Cabanes, C., Gondar, O. O., Luján, F. M., & Satué-Gracia, E. M. (2025) · BMC Family Practice · doi:10.1186/s12875-025-02826-w · Cited by 1
Kramer, H., & Navaneethan, S. D. (2019) · Nephrology Self-Assessment Program · doi:10.1681/nsap.2019.18.4.9 · Cited by 1
Beyond HDL-Cholesterol: The Search for Functional Biomarkers of High Density Lipoproteins
von Eckardstein, A. (2022) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2022.2.e5 · Cited by 1
Ou, J., Li, H.-M., Shi, M., & Ou, Z. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_1054 · Cited by 1
Al‐Aly, Z. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.11.95
Self-citationHypertriglyzeridämie und HDL-Mangel
von Eckardstein, A. (2017) · CardioVasc · doi:10.1007/s15027-017-1275-x
Yu, Y., Li, M., Huang, X. B., Zhou, W., Wang, T., Zhu, L., Ding, C., Yu, T., Bao, H., & Cheng, X. (2020) · Research Square · doi:10.21203/rs.3.rs-52204/v1
The role of HDL cholesterol as a measure of 10-year cardiovascular risk should be re-evaluated
Güleç, S., & Erol, Ç. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab080
Chang, L., Chen, X., & Lian, C. (2021) · Research Square · doi:10.21203/rs.3.rs-700309/v1
Denton, N. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780198865278.003.0003
The relation between coronary artery disease and newly diagnosed dysglycemia
Cam, T. D., & Ton, T. T. (2022) · Perfusion · doi:10.1177/02676591221113970
Remnant Cholesterol and Status of Dyslipidemia in Hemodialysis Patients
杜, 柯. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.127880
Chen, C., Feng, Q., Yang, M., Chen, S., Sun, H., Zhang, Y., Pu, S., Chen, H., Su, D., Guo, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1784859/v1
Association of 21 Physiological Indicators with All-Cause Mortality: A Population-Based Cohort StudyPreprint
Li, J., & Zhang, Q. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4089483
Paradoxical mortality differential of HDL cholesterol
Mukhopadhyay, J., Mallik, D., & Garg, S. (2023) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v14i5.50292
han, H., Jung, D., Heo, S., & Lee, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-3932993/v1
Luo, X., Guo, Q., Wang, J., Li, Y., Zhao, J., Huang, B., & Chen, X. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1341663
Ribas-Seguí, D., Forcadell-Peris, M. J., Vila-Córcoles, Á., de Diego‐Cabanes, C., Gondar, O. O., Luján, F. M., & Satué-Gracia, E. M. (2024) · Research Square · doi:10.21203/rs.3.rs-4506982/v1
Han, H. Y., Jung, D., Heo, S.-J., & Lee, Y. J. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02495-2
Mansoori, A., Behkamal, B., Darroudi, S., Nateghi, N., Soflaei, S. S., Shahri, B., Alimi, H., Esmaily, H., Ferns, G. A., Ghayour‐Mobarhan, M., et al. (2025) · Artery Research · doi:10.1007/s44200-025-00089-5
Metadata
- Authors
- Bowe, B., Xie, Y., Xian, H., Balasubramanian, S., Zayed, M. A., & Al-Aly, Z.
- Affiliations
- Clinical Epidemiology Center, Research and Education Service,
- Saint Louis University (US)
- Corresponding author
- Bowe, Benjamin
- Xie, Yan
- Xian, Hong
- Balasubramanian, Sumitra
- Zayed, Mohamed A.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2016-08-11
- Volume
- 11
- Issue
- 10
- Pages
- 1784-1793
- ISSN
- 1555-9041 (ISSN-L)
- 1555-905X
- PMC
- PMC5053782
- OpenAlex
- W2512996508
- Cited by
- 213
- References
- 28
- Citations by year
- 2026: 7 · 2025: 18 · 2024: 16 · 2023: 11 · 2022: 26 · 2021: 46 · 2020: 21 · 2019: 26 · 2018: 16 · 2017: 22 · 2016: 4
- FWCI
- 25.09
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Keywords
- HDL cholesterol, all-cause mortality, estimated glomerular filtration rate, kidney disease, veterans, U-shaped relationship, coronary artery disease, comorbidities, mortality risk, lipid-lowering therapy, cardiovascular risk stratification, mortality prediction model, dialysis, mortality risk reduction
- MeSH terms
- Aged, Coronary Artery Disease, Female, Glomerular Filtration Rate, Heart Failure, Humans, Kidney Diseases, Cholesterol, HDL, Longitudinal Studies, Male, Middle Aged, Mortality, Risk Factors, United States, Veterans, Comorbidity, Survival Rate, Proportional Hazards Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
